TABLE 1.
Characteristics and comorbid diseases of the study population (n=420)
| Characteristic | Polypharmacy (n=135) | Non-polypharmacy (n=285) | P1 | P2 |
|---|---|---|---|---|
| Age, mean±SD | 76.85±7.87 | 71.5±8.57 | <0.001 | – |
| Education years, mean±SD | 6.3±4.61 | 8.35±4.75 | <0.001 | 0.008 |
| Female, % | 72 | 63 | 0.13 | – |
| Number of drugs, mean±SD | 8.1±2.89 | 1.98±1.5 | <0.001 | – |
| Comorbid diseases, % | ||||
| Hypertension | 77.8 | 42 | <0.001 | <0.001 |
| Ischemic heart disease | 27.8 | 5.3 | <0.001 | <0.001 |
| Congestive heart failure | 2.6 | 3.2 | 1.0 | – |
| Cerebrovascular disease | 11.1 | 3.2 | 0.003 | 0.016 |
| Peripheral artery disease | 10.3 | 4.2 | 0.003 | 0.118 |
| Diabetes mellitus | 39.3 | 10.2 | <0.001 | <0.001 |
| Hyperlipidemia | 23.1 | 11 | 0.003 | 0.002 |
| Dementia | 23.9 | 9.1 | <0.001 | 0.004 |
| COPD | 22.4 | 3.5 | <0.001 | <0.001 |
| Thyroid disease | 25.6 | 12.7 | 0.003 | 0.002 |
| Osteoporosis | 38.2 | 17.7 | <0.001 | <0.001 |
| Falls | 45.3 | 22.3 | <0.001 | <0.001 |
| CCI, mean±SD | 1.34±1.02 | 0.53±0.86 | <0.001 | <0.001 |
SD: Standard deviation; CCI: Charlson comorbidity index; COPD: Chronic obstructive pulmonary disease; SD: Standard deviation; P1: P-values for comparison of two groups; P2: P-values for comparison of polypharmacy and non-polypharmacy group after adjusted for age.